Skip to Content

BRAF Mutational Analysis

Indication

To identify activating point mutations in the kinase domain of BRAF, an oncogene that is frequently mutated in many human malignancies including melanoma, colorectal cancer (CRC), papillary thyroid cancer, and lung cancer. BRAF mutations are found in sporadic microsatellite instability-high (MSI-H) CRC but not in CRC arising from HNPCC and therefore in concert with the hMLH1 methylation assay may be useful in determining germline versus sporadic MSI-H CRC. In addition, point mutations in BRAF may identify patients likely to benefit from treatment by BRAF inhibitors.

Methodology

Next Gen Sequencing of codons 444, 464, 466, 469, 471, 581, 586, 587, 592, 594-597, 599-602, 601 and 605 is performed on tumor cells extracted from paraffin embedded tissue.  This assay is also available as PCR-based pyrosequencing of DNA to examine codons 595 to 600 from exon 15 (the most common mutation site) and codons 468 to 474 from exon 11 of the BRAF gene.

Sensitivity

Tumor clone must comprise at least 10% of the cells in the sample.

Turnaround Time

10 days

Sample Requirements

Formalin-fixed, paraffin embedded tissue blocks containing adequate amounts of tumor to be analyzed (see above sensitivity), with areas to be tested indicated. Comparison of normal and tumor, or several different areas of tumor can be done, for additional charge.

If testing by sequencing, please specify whether exon 11 is to be sequenced in addition to exon 15.

Please provide a copy of the corresponding pathology report.

CPT Codes

81210

Additional charges may apply for tissue extraction.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


© 2014 The University of Texas MD Anderson Cancer Center